| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 292.75 | 10.8% |
| Total Income | 300.61 | 10.5% |
| Expenditure | 283.04 | 4.5% |
| PBT | 17.57 | 55.3% |
| Net Profit | 13.90 | 50.0% |
| OPM | 11.78% | 3.77pp |
| NPM | 4.62% | 3.66pp |
| EPS | 10.83 | 50.0% |
Neuland Q1FY26 Total Income at Rs.300.6 crore; EBITDA at Rs.42.1 crore
31 Jul 2025 · 31 Jul 2025, 04:42 pm
Summary
Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the first quarter ended June 30, 2025. The company's total income for Q1FY26 was Rs.300.6 crore and EBITDA was Rs.42.1 crore.
Key Highlights
- 1
Q1FY26 Total income at Rs.300.6 crore
- 2
EBITDA at Rs.42.1 crore
- 3
Q1FY25 includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores
- 4
Investments are proceeding according to plan and would be drivers of short as well as long term growth
- 5
Focus on cost optimization opportunities across products and processes
- 6
Substantial growth this year from commercial molecules
- 7
Significant influx of new business from existing and new customers along with customers’ pipeline projects making exciting progress
- 8
Continuing to invest in people and capabilities
- 9
Q1 FY26 Earnings Call at 17:30 hrs. IST on Thursday, July 31, 2025
Management Comments
Mr. Sucheth Davuluri
Vice-Chairman and Chief Executive Officer
While Q1 FY26 has been below par as a result of the flow of customer orders, it doesn’t change our outlook on the healthy growth that we anticipate this financial year. The investments we have announced are proceeding according to plan and would be drivers of short as well as long term growth. We continue to focus on cost optimization opportunities across products and processes which will enable us to further strengthen our position in key products.
Mr. Saharsh Davuluri
Vice Chairman and Managing Director
We see substantial growth this year from our commercial molecules even as there is a significant influx of new business from existing and new customers along with customers’ pipeline projects making exciting progress. Given customers’ interest and evolving expectations we are continuing to invest in our people and capabilities which should see Neuland further differentiated as a CDMO with deep expertise as well as an agile innovative partner.
Informational and educational content only. Not investment advice.